收费全文 | 2370647篇 |
免费 | 172939篇 |
国内免费 | 3398篇 |
耳鼻咽喉 | 32215篇 |
儿科学 | 76393篇 |
妇产科学 | 63064篇 |
基础医学 | 351265篇 |
口腔科学 | 63925篇 |
临床医学 | 213313篇 |
内科学 | 462318篇 |
皮肤病学 | 52171篇 |
神经病学 | 187095篇 |
特种医学 | 88590篇 |
外国民族医学 | 492篇 |
外科学 | 356868篇 |
综合类 | 47707篇 |
现状与发展 | 12篇 |
一般理论 | 875篇 |
预防医学 | 184344篇 |
眼科学 | 54683篇 |
药学 | 176469篇 |
12篇 | |
中国医学 | 4626篇 |
肿瘤学 | 130547篇 |
2021年 | 19253篇 |
2019年 | 19814篇 |
2018年 | 27387篇 |
2017年 | 20574篇 |
2016年 | 23024篇 |
2015年 | 25969篇 |
2014年 | 36585篇 |
2013年 | 54695篇 |
2012年 | 75816篇 |
2011年 | 80645篇 |
2010年 | 47809篇 |
2009年 | 45365篇 |
2008年 | 75785篇 |
2007年 | 80843篇 |
2006年 | 81685篇 |
2005年 | 79232篇 |
2004年 | 75660篇 |
2003年 | 72918篇 |
2002年 | 70617篇 |
2001年 | 108992篇 |
2000年 | 111667篇 |
1999年 | 93767篇 |
1998年 | 27312篇 |
1997年 | 23937篇 |
1996年 | 24299篇 |
1995年 | 22936篇 |
1994年 | 21104篇 |
1993年 | 19907篇 |
1992年 | 72198篇 |
1991年 | 70273篇 |
1990年 | 68572篇 |
1989年 | 65827篇 |
1988年 | 60442篇 |
1987年 | 59271篇 |
1986年 | 55365篇 |
1985年 | 53168篇 |
1984年 | 39460篇 |
1983年 | 33552篇 |
1982年 | 20031篇 |
1979年 | 35974篇 |
1978年 | 25747篇 |
1977年 | 21343篇 |
1976年 | 20421篇 |
1975年 | 21910篇 |
1974年 | 26235篇 |
1973年 | 24875篇 |
1972年 | 23266篇 |
1971年 | 22102篇 |
1970年 | 20289篇 |
1969年 | 19356篇 |
Background
Obesity is a risk factor for acetabular component malposition when total hip arthroplasty is performed with manual techniques. The utility of imageless navigation in obese patients remains unknown. This study compared the accuracy and precision of imageless navigation for component orientation between obese and nonobese patients.Methods
A total of 459 total hip arthroplasties performed for osteoarthritis using imageless navigation were reviewed from a single surgeon’s institutional review board–approved database. Einzel-Bild-Roentgen Analyse determined component orientation on 6-week postoperative anteroposterior radiographs. Mean orientation error (accuracy) and precision were compared between obese (body mass index ≥ 30 kg/m2) and nonobese patients. Regression analysis evaluated the influence of obesity on component position.Results
The difference in mean inclination and anteversion between obese and nonobese groups was 1.1° (43.0° ± 3.5°; range, 35.8°-57.8° vs 41.9° ± 4.4°; range, 33.0°-57.1° and 24.9° ± 6.3°; range, 14.2°-44.3° vs 23.8° ± 6.6°; range, 7.0°-38.6°, respectively). Inclination precision was better for nonobese patients. No difference in inclination accuracy or anteversion accuracy or precision was detected between groups. And 83% of components were placed within the target range. There was no relationship between obesity (dichotomized) and component placement outside the target ranges for inclination, anteversion, or both. As a continuous variable, increased body mass index correlated with higher odds of inclination outside the target zone (odds ratio, 1.06; P = .001).Conclusion
Using imageless navigation, inclination orientation was less precise for obese patients, but the observed difference is likely not clinically relevant. Accurate superficial registration of landmarks in obese patients is achievable, and the use of imageless navigation similarly improves acetabular component positioning in obese and nonobese patients.Level of Evidence
Therapeutic Level IV. 相似文献Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library.
Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug’s dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD. 相似文献